Bluejay Diagnostics develops rapid, near-patient diagnostic testing for critical care settings through its Symphony™ platform. The company’s lead product candidate, the Symphony™ IL-6 Test, is designed to measure interleukin-6 for sepsis triage, patient monitoring, and risk assessment, with sample-to-result testing described at approximately 20 minutes.
Bluejay news commonly covers SYMON clinical studies, IL-6 biomarker data, conference presentations, manufacturing readiness for Symphony cartridges, antibody production for test components, and regulatory preparation. Company updates also include financing activity, warrant exercises, reverse stock splits, and other capitalization matters. The Symphony System does not yet have U.S. FDA regulatory clearance and requires authorization before it can be marketed as a diagnostic product in the United States.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.